Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments
- 30 January 2018
- journal article
- review article
- Published by Taylor & Francis in Minimally Invasive Therapy & Allied Technologies
- Vol. 27 (2) , 69-80
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Only 30–40% of patients diagnosed with HCC are candidates for curative treatment options. The remaining majority of patients undergo local, regional or systemic palliative therapies. Transvascular therapy of HCC takes advantage of the fact that hypervascularized HCCs receive their main perfusion from the hepatic artery. In this context transvascular therapy describes different therapies: bland embolization (transarterial embolization, TAE), cTACE (conventional transarterial chemoembolization), DEB-TACE (TACE with drug-eluting beads, DEB) and SIRT (selective internal radiation therapy, radioembolization). cTACE is the most common type of transvascular treatment and represents a combination of the intra-arterial use of a chemotherapeutic agent and embolization. There is no standardized regimen for cTACE. It remains unclear whether the intra-arterial application of a chemotherapeutic agent is definitely required, because bland embolization alone using very small spherical particles shows tumor necrosis comparable to cTACE. For DEB-TACE microparticles loaded with a chemotherapeutic drug combine the advantages of cTACE and bland embolization.Keywords
This publication has 49 references indexed in Scilit:
- Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular CarcinomaGastroenterology, 2011
- Bland Embolization in Patients with Unresectable Hepatocellular Carcinoma Using Precise, Tightly Size-Calibrated, Anti-Inflammatory Microparticles: First Clinical Experience and One-Year Follow-UpCardioVascular and Interventional Radiology, 2009
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and InvasivenessAmerican Journal of Gastroenterology, 2008
- Multivariate Analysis of the Predictors of Survival for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Focusing on uperselective ChemoembolizationKorean Journal of Radiology, 2008
- Transarterielle Chemoembolisation (TACE) des hepatozellulären Karzinoms: Technik, Indikationsstellung und ErgebnisseRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2007
- Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2007
- Particle embolization of recurrent hepatocellular carcinoma after hepatectomyCancer, 2006
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Pharmacokinetics and toxicity of intraarterial Adriamycin for hepatocellular carcinoma: Effect of coadministration of lipiodolJournal of Hepatology, 1991